- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2012-05-18 12:59:18
- Reporting Period:
- Filing Date:
- Filing Date Changed:
- Accepted Time:
- 2012-05-18 13:59:18
- Original Submission Date:
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|827809||Qlt Inc||QLTI||Pharmaceutical Preparations (2834)||000000000|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1360509||Florian Schonharting||Ostergade 24A, 1 |
Copenhagen K G7
|1451330||K/s Equity Public Nb||Ostergade 24A, 1 |
Copenhagen K G7
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings|
|Common Shares, No Par Value||Acquisiton||2012-05-16||50,000||$6.67||7,447,626|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.70 inclusive. The Reporting Owners undertake to provide to QLT, Inc., any security holder of QLT, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- Reported shares are owned directly by NB Public Equity K/S (the "Fund"), and indirectly by the other listed Reporting Owner.
- Florian Schonharting is a direct investor in a limited partner in the Fund and a director of Nordic Biotech Advisors ApS, which owns 100% of the shares of NB Public Equity Komplementar ApS, the general partner of the Fund. Mr. Schonharting disclaims beneficial ownership in the securities, except to the extent of his pecuniary interest therein.
Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).